Loading data for VYGR — first visit, this takes a few seconds.

Alert

Voyager Therapeutics Inc. (VYGR)

NasdaqGS: VYGR · Real-Time Price · USD

3.39

+0.07 (2.11%)

At close: Aug 21, 2026, 8:00 PM

3.39

-0.09%

After-hours: 7:41 PM

The price, the headline numbers and the latest news, in one place.

2.11% (1D)

No data available

Bid	2.46
Market Cap	208.88M
Revenue (ttm)	34.46M
Net Income (ttm)	-107.73M
	1.31
	-1.81
	n/a
	-2.65
P/B (ttm)	1.18
P/S (ttm)	6.06
Earnings Date	Nov 9, 2026

Ask	4.27
Volume	424,442
Avg. Volume (20D)	608,211
Open	3.36
Previous Close	3.32
Day's Range	3.30 - 3.44
52-Week Range	2.94 - 5.55
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; AL...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 11, 2015

Employees 141

Stock Exchange NasdaqGS

Ticker Symbol VYGR

Website https://www.voyagertherapeutics.com

Full Company Profile

Financial Performance

In 2025, Voyager Therapeutics's revenue was 40.37M, a decrease of -49.53% compared to the previous year's 80M. Earnings were -119.72M, an increase of 84.18%.

Financial Statements

Earnings Surprise

Voyager Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $3.17M misses estimates by $0, with -39.13% YoY decline.
EPS of -0.4 exceeds estimates by 0.11, with 29.82% YoY growth.

Next Earnings Release

Voyager Therapeutics Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Zacks

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 month ago · Barrons.com

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

1 month ago · 24/7 Wall St.

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for...

1 month ago · Insider Monkey

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside. Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, ...

2 months ago · Simply Wall St.

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Page 1 of 2

Voyager Therapeutics Inc. (VYGR)